In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...
A study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...
Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...
News Medical on MSN10h
Research identifies iron as crucial driver of stroke-related cell death processesIschemic stroke continues to rank among the top causes of death and long-term disability globally. While advances in acute treatments like clot retrieval and thrombolysis have improved outcomes, the ...
Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.
Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The fibrin-specific plasminogen activator ...
The "Stroke - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of Stroke Clinical trials scenario ...
Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...
Validcare CEO Patrick McCarthy said, “We are very excited to be working with Algernon Neuro on their upcoming, ground-breaking Phase 2a DMT stroke study and we are very pleased to become an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback